FORBAXIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Forbaxin, and what generic alternatives are available?
Forbaxin is a drug marketed by Forest Labs and is included in one NDA.
The generic ingredient in FORBAXIN is methocarbamol. Sixty-seven suppliers are listed for this compound. Additional details are available on the methocarbamol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Forbaxin
A generic version of FORBAXIN was approved as methocarbamol by REGCON HOLDINGS on July 21st, 2017.
US Patents and Regulatory Information for FORBAXIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Forest Labs | FORBAXIN | methocarbamol | TABLET;ORAL | 085136-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
